Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
04 January 2022 - 11:11PM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that
Ron Cohen, MD, President and CEO, will present at the H.C.
Wainwright BIOCONNECT Virtual Conference, taking place from January
10 – 13, 2022.
H.C. Wainwright BIOCONNECT Conference Date: January 10 –
13, 2022 Presentation Time: Available on-demand January 10, 2022 at
7:00 am ET Webcast:
https://journey.ct.events/view/af6d1ca2-50d5-48b4-a5ce-ae85ca68054f
Conference Website: Click here
The presentation can also be accessed from Acorda’s website:
https://ir.acorda.com/investors/investor-events/default.aspx
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and
improve the lives of people with neurological disorders. INBRIJA®
is approved for intermittent treatment of OFF episodes in adults
with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA
is not to be used by patients who take or have taken a nonselective
monoamine oxidase inhibitor such as phenelzine or tranylcypromine
within the last two weeks. INBRIJA utilizes Acorda’s innovative
ARCUS® pulmonary delivery system, a technology platform designed to
deliver medication through inhalation. Acorda also markets the
branded AMPYRA® (dalfampridine) Extended Release Tablets, 10
mg.
Forward-Looking Statements
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: we may not be able to successfully
market AMPYRA, INBRIJA or any other products under development; the
COVID-19 pandemic, including related restrictions on in-person
interactions and travel, and the potential for illness, quarantines
and vaccine mandates to affect our management, employees or
consultants or those that work for other companies we rely upon,
could have a material adverse effect on our business operations or
product sales; our ability to attract and retain key management and
other personnel, or maintain access to expert advisors; our ability
to raise additional funds to finance our operations, repay
outstanding indebtedness or satisfy other obligations, and our
ability to control our costs or reduce planned expenditures; risks
associated with the trading of our common stock and our reverse
stock split; risks related to our corporate restructurings,
including our ability to outsource certain operations, realize
expected cost savings and maintain the workforce needed for
continued operations; risks associated with complex, regulated
manufacturing processes for pharmaceuticals, which could affect
whether we have sufficient commercial supply of INBRIJA to meet
market demand; our reliance on third-party manufacturers for the
production of commercial supplies of AMPYRA and INBRIJA;
third-party payers (including governmental agencies) may not
reimburse for the use of INBRIJA at acceptable rates or at all and
may impose restrictive prior authorization requirements that limit
or block prescriptions; reliance on collaborators and distributors
to commercialize INBRIJA and AMPYRA outside the U.S.; competition
for INBRIJA and AMPYRA, including increasing competition and
accompanying loss of revenues in the U.S. from generic versions of
AMPYRA (dalfampridine) following our loss of patent exclusivity;
the ability to realize the benefits anticipated from acquisitions,
among other reasons because acquired development programs are
generally subject to all the risks inherent in the drug development
process and our knowledge of the risks specifically relevant to
acquired programs generally improves over time; the risk of
unfavorable results from future studies of INBRIJA (levodopa
inhalation powder) or from other research and development programs,
or any other acquired or in-licensed programs; the occurrence of
adverse safety events with our products; the outcome (by judgment
or settlement) and costs of legal, administrative or regulatory
proceedings, investigations or inspections, including, without
limitation, collective, representative or class-action litigation;
failure to protect our intellectual property, to defend against the
intellectual property claims of others or to obtain third-party
intellectual property licenses needed for the commercialization of
our products; and failure to comply with regulatory requirements
could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220104005577/en/
Tierney Saccavino (914) 326-5104 tsaccavino@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024